Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- HIV -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (119)	8/17/2009 10:49:34 AM
From: Elroy Jetson	Respond to of 155

That's good news. This looks like the poster Jules abstracted his report from. ias2009.org .

To: idos who wrote (119)	9/3/2009 11:10:28 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 155

Antibodies found that prevent HIV from causing severe AIDS Scientists were able to isolate two antibodies responsible for resistance to the disease in an African patient. The discovery could be key to the development of a vaccine. September 4, 2009 -- Thomas H. Maugh II -- latimes.com After 15 years of futile searching for a vaccine against the AIDS virus, researchers are reporting the tantalizing discovery of antibodies that can prevent the virus from multiplying in the body and producing severe disease. They do not have a vaccine yet, but they may well have a road map toward the production of one. A team based at the Scripps Research Institute in La Jolla reports in Friday's journal Science that they have isolated two so-called broadly neutralizing antibodies that can block the action of many strains of HIV, the virus responsible for AIDS. Crucial to the discovery is the fact that the antibodies target a portion of HIV that researchers had not previously considered in their search for a vaccine. Moreover, the target is a relatively stable portion of the virus that does not participate in the extensive mutations that have made HIV able to escape from antiviral drugs and previous experimental vaccines. "This is opening up a whole new area of science," said Dr. Seth Berkley, president and chief executive of the International AIDS Vaccine Initiative, which funded and coordinated the research. At least 33 million people worldwide are infected with HIV, and at least 25 million have died from AIDS, according to the World Health Organization. Two large trials of experimental vaccines have failed -- the most recent, in 2007, because the vaccine apparently made people more susceptible to infection. To find the neutralizing antibodies, researchers collected blood samples from more than 1,800 people in Thailand, Australia and Africa who had been infected with HIV for at least three years without the infection proceeding to severe disease. Such individuals are most likely to produce antibodies that interfere with the replication of the virus. Researchers at Monogram Biosciences Inc. in South San Francisco then studied the samples most resistant to infection. A team from Theraclone Sciences in Seattle then isolated the antibodies responsible for the resistance. They ultimately isolated two antibodies, called PG9 and PG16, from one African patient. The antibodies were able to block the activity of about three-quarters of the 162 separate strains of HIV they tested it against. Immunologist Dennis Burton of Scripps and his colleagues then showed that the antibodies bind to regions of two proteins on the surface of the virus, called gp120 and gp41, that help the virus invade cells. These regions had never before been considered as targets for vaccines. Researchers still have a long way to go to produce a vaccine, however. The antibodies themselves could potentially be used as a treatment for infected patients who develop severe disease. But the long-term hope is to find molecules, either synthetic or natural, that can stimulate the body to produce the broadly neutralizing antibodies. Such molecules could potentially be the basis for a successful vaccine. .